Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from
Beam Therapeutics lost more money per share than experts thought it would, and made way less sales than expected. When a company loses more and sells less, it tells us the business is moving slower than people hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.